# Datroway (Datopotamab Deruxtecan) Recommended for EU Approval in Triple-Negative Breast Cancer

> fda · REPORTED · 2026-07-08

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate Datroway (datopotamab deruxtecan) received a positive CHMP recommendation for approval in the EU for triple-negative breast cancer, based on the TROPION-Breast02 trial, further cementing ADCs as the dominant treatment modality in TNBC.

About AstraZeneca / Daiichi Sankyo: AstraZeneca and Daiichi Sankyo co-develop Datroway, a TROP2-directed antibody-drug conjugate designed to deliver targeted chemotherapy to tumor cells, serving patients with triple-negative and other advanced breast cancer subtypes.

- Company: AstraZeneca / Daiichi Sankyo
- Sector: oncology
- Primary source: https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.